Pfizer/Allergan: Breaking Up Is Hard To Do (Unless There’s A New Tax Law)
The breakup fee for the Pfizer/Allergan merger would be $3.5bn in certain instances, but much lower, just $400m in expense reimbursement, if a party decides to terminate the deal due to an adverse change in law.
You may also be interested in...
Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.
The company showcased its expanded cancer drug pipeline two months after completing the acquisition of Seagen last year.
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.